Reproductive health

Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act

Retrieved on: 
Friday, July 22, 2022
Louisiana House of Representatives, Insurance, Citric acid, Sex, Legislation, Birth, Woman, SAN, SEC, Birth control, Chlamydia, House, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, Clinical trial, Gonorrhea, Representative, FDA, Company, Reproductive health, Annual report

SAN DIEGO, July 22, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act.

Key Points: 
  • SAN DIEGO, July 22, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act.
  • "Today we applaud the U.S. House of Representatives for passing The Right to Contraception Act, which would codify into law the fundamental right to safe and easy access to contraception," saidSaundra Pelletier, Chief Executive Officer of Evofem Biosciences.
  • Providing women with their choice of contraception should not be up for debate."
  • Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea.

Evofem Partners with a360 Media to Support Phexxi® Prescription Growth

Retrieved on: 
Thursday, July 21, 2022
Awareness, Citric acid, Sex, Woman's World, Female, Woman, SEC, Chlamydia, Partnership, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, Health, Prescription, Gonorrhea, EVP, FDA, Company, Lactic acid, In Touch Weekly, Reproductive health, Annual report, Publishing, Birth control, Lactic acid/citric acid/potassium bitartrate, Media

SAN DIEGO, July 21, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced an agreement between Evofem and a360 Media under which Phexxi® (lactic acid, citric acid, and potassium bitartrate) branded content will appear in some of the most widely read entertainment and lifestyle magazines and websites in the U.S.

Key Points: 
  • a360 Media reaches 60 million unique digital visitors per month and another 27 million via print audiences.
  • One out of every three a360 Media readers and digital users is a female between the ages of 18 and 34, making this partnership an ideal union.
  • To date, 72% of the prescriptions through the Phexxi telehealth program are to women in this demographic.
  • After the first two weeks of the partnership, new prescriptions of Phexxi - a hormone-free, on-demand prescription contraceptive vaginal gel - were up 16%.

Inaugural Fibroids Awareness Day aims to break the silence and isolation around misunderstood disease that will impact 70% of all women by age 50

Retrieved on: 
Thursday, July 21, 2022
GLOBE, Hospital, Woman, Infertility, Uterine fibroid, Obstetrics, CHUM, Abdominal pain, Awareness, Social isolation, Disease, Pain, Reproductive health, Hope, Gynaecology, Anemia, Birth control, Fibroid

It gave me hope and a support system where I had access to all these women with the same lived experience.

Key Points: 
  • It gave me hope and a support system where I had access to all these women with the same lived experience.
  • Thirty to 50% of women are carriers of fibroids, with symptoms that vary from woman to woman.
  • In honour of Fibroids Awareness Day, Canadians are encouraged to share their stories using the hashtag #FightingFibroids and #Vivre100Fibromes.
  • Founded in 2016, Vivre 100 Fibromes is a nonprofit organization whose mission is to improve the care of women with uterine fibroids.

Femasys To Host Key Opinion Leader Event on FemBloc, a First-of-its-Kind Medical Solution for Permanent Birth Control and an Important Option for Women Post Overturn of Roe v. Wade

Retrieved on: 
Wednesday, July 20, 2022
Ipas, Gynaecology, Anesthesia, World, Obstetrics and gynaecology, GLOBE, MPH, Organic, Population Services International, Stanford University Medical Center, Global Medical Aid, Birth, Woman, Special, Infertility, Research, Planned Parenthood, KOL, NASDAQ, World Health Organization, Cervical cancer, Roe v. Wade, Q&A, Ministry, Technology, Publication, Tubing (recreation), Pathfinder, Reproductive health, International, SPIRES, Hormone, Stanford University, Parenthood, Non-governmental organization, Republic, Medical device, Birth control, Obstetrics, MD, Health

Dr. Blumenthal has a distinguished career in Obstetrics & Gynecology spanning close to 40 years and has conducted advocacy work in Womens Health on a global basis.

Key Points: 
  • Dr. Blumenthal has a distinguished career in Obstetrics & Gynecology spanning close to 40 years and has conducted advocacy work in Womens Health on a global basis.
  • Femasys FemBloc, a novel approach to permanent birth control, will be discussed as an important potential medical solution as it pertains to womens contraceptive options and choices, especially given the recent overturning of Roe v. Wade.
  • Confirmation of procedure success can be achieved after 90 days, which would provide women with a certainty no other option can achieve.
  • Its two lead product candidates are FemBloc permanent birth control and FemaSeed localized directional insemination for infertility.

Fulgent Genetics to Announce Second Quarter 2022 Financial Results on Thursday, August 4, 2022

Retrieved on: 
Tuesday, July 19, 2022
Science, Biotechnology, Research, Oncology, Health, Infectious Diseases, Genetics, Other Health, Investor, Reproductive health, Genetic testing, Battle of Saint-Fulgent, NGS, Technology, NASDAQ, Degenerative disease, Genetics, Cloud computing, Company, Health, Pharmaceutical industry

Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022.
  • An audio replay will be available in the Investors section of the companys website.
  • Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health.
  • Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times.

Bellabeat Debuts Ivy Health Tracker in Chic Jet Black & Snow White Ahead of Fall Fashion Season

Retrieved on: 
Tuesday, July 19, 2022
Hedera, Athlete, Woman, Leaf, Pregnancy, Water, AI, Menstrual cycle, Reproductive health, Bellabeat, Multimedia, Silicon, Ovulation, Femtech, Mobile phone, Birth control

NEW YORK, July 19, 2022 /PRNewswire/ -- Pioneer for women in the tech and wellness space via technology wearables, Bellabeat Inc. (https://bellabeat.com/) announced today the addition of two new stunning colors to their Ivy wearable collection. Drawn from elegant minimalism, the wearable tracking bracelet is now available in two solid colors; 'Jet Black' in-laid within a striking matte hardware detail and 'Snow' with a rose gold hardware trim, perfect for the white winter-loving fashionista. The adjustable strap aligns in color with the centerpiece of your choice, ensuring a bespoke fit. Among health and fitness trackers, Ivy stands out with its fashionable, edgy look that matches any style. With no display, Ivy's non-intrusive design keeps your data private and visible only when synced with the Bellabeat app, the only health tracker designed and engineered for women. Ivy's advanced sensors monitor the body's reactions and daily habits continuously throughout the day and night at a charged capacity - providing women with a complete insight into the pace of life. Elegantly designed, The Ivy is a smart bracelet and one gem of a find retailing at $249 on bellabeat.com. 

Key Points: 
  • Ivy helps you to sync with your body and discover its natural wisdom by correlating your biometric and lifestyle data to the four phases of the menstrual cycle.
  • Ivy helps you tune in with your body's rhythm and track your period, ovulation, pregnancy, or birth control.
  • For media inquiries on the Bellabeat Ivy or its participating athletes in conjunction with it, please email Monique Tatum [email protected] or call 877.841.7244.
  • The Bellabeat team previously released the disruptive Leaf health tracking jewelry for women and the first smart water bottle powered by AI.

Illumina Announces Inaugural Illumina Genomics Forum with a Conversation with Former U.S. President Barack Obama

Retrieved on: 
Monday, July 18, 2022
Research, Cancer, LinkedIn, Care Act 2014, Agriculture, Genome, Therapy, Affordable Care Act, DNA, Twitter, Genomics, Reproductive health, Forum, NASDAQ, Infection, Instagram, Health, Diagnosis, Population health, YouTube, Q&A, SAN, Renewable energy, Medicine, Facebook, Illumina

SAN DIEGO, July 18, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that former President of the United States Barack Obama will participate in a moderated Q&A conversation at the inaugural Illumina Genomics Forum, the company's global event focused on advancing genomics-driven health. The Forum will take place in San Diego from September 28 through October 1, with virtual sessions to be held on October 4.

Key Points: 
  • The Forum will take place in San Diego from September 28 through October 1, with virtual sessions to be held on October 4.
  • President Obama will participate in a fireside chat on the evening of Wednesday, September 28.
  • Few presidents have fought for equitable, accessible, and affordable healthcare as persistently and passionately as Barack Obama," said Kathryne Reeves, Chief Marketing Officer of Illumina.
  • "The era of genomics is now and I cannot think of a more appropriate and timely keynote speaker for the inaugural Illumina Genomics Forum, as we continue advocating for expanded access to the life-saving potential of genomics."

Illumina to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022

Retrieved on: 
Thursday, July 14, 2022
Conference, YouTube, Corporate development, LinkedIn, Interim, Agriculture, SAN, Instagram, Reproductive health, Illumina, Inc., Interest, Research, Twitter, Genome, Health, DNA, NASDAQ, Illumina, Facebook

SAN DIEGO, July 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2022 following the close of market on Thursday, August 11, 2022.

Key Points: 
  • SAN DIEGO, July 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2022 following the close of market on Thursday, August 11, 2022.
  • The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, August 11, 2022.
  • Interested parties may access the live teleconference through the Investor Info section of Illumina's website under the "company" tab at www.illumina.com .
  • Alternatively, individuals can access the call by dialing 866.409.1555 or +1.313.209.4906 outside North America, both with Conference ID 6659694.

WCG Cares Unveils Rebrand, Changes Name to Catalyst Global

Retrieved on: 
Thursday, July 14, 2022
Instagram, GLOBE, Woman, LinkedIn, Twitter, Health, Reproductive rights, SRH, Exercise, Reproductive health, Toy, Birth control, Facebook

CARLSBAD, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- WCG Cares, an international non-profit organization committed to increasing access to critical sexual and reproductive health (SRH) products and services in low- and middle-income countries, announced an extensive rebrand today, changing its name to Catalyst Global.

Key Points: 
  • CARLSBAD, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- WCG Cares, an international non-profit organization committed to increasing access to critical sexual and reproductive health (SRH) products and services in low- and middle-income countries, announced an extensive rebrand today, changing its name to Catalyst Global.
  • Is the organization in its current form best set up to spark bold change?
  • The logo with blended, vibrant colors in the "C" represents the change and transformation Catalyst Global brings about as the organization engages with partners in projects and initiatives across the globe.
  • For more information, visit www.catalystglobal.org , connect with us on LinkedIn , Facebook , Twitter and Instagram or email us at [email protected].

Illumina Among First in the World to Receive Approval of Science-Based Net-Zero Target

Retrieved on: 
Thursday, July 14, 2022
Zero, Goal, Paris Agreement, Security (finance), U.S. Securities and Exchange Commission, Transport, Corporation, Science, YouTube, LinkedIn, Genomics, GHG, Targets, Certification, Agriculture, SAN, Review, Instagram, List of climate change initiatives, Time, Investment, Reproductive health, Risk, Illumina, Inc., Cooperative Mechanisms under Article 6 of the Paris Agreement, Research, Twitter, Genome, Health, DNA, Form 10-K, Corporate social responsibility, NASDAQ, Renewable energy, Illumina, Facebook

SAN DIEGO, July 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative (SBTi). This includes validation of Illumina's corporate greenhouse gas (GHG) emissions reduction targets by the organization.

Key Points: 
  • The SBTi is a global body that enables businesses to set ambitious emissions reduction targets in line with the latest climate science.
  • "Illumina proudly joins the SBTi as the first genomics company in the world with a verified, science-based, net-zero target," said John Frank, Chief Public Affairs Officer of Illumina.
  • In January 2022, it opened this certification to all companies, and Illumina was among the first to request verification of its net-zero target.
  • Now, Illumina is among the first group of companies in the world to receive validation of its science-based targets.